VolitionRX (NYSEAMERICAN:VNRX), traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.
The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions. These assays are undergoing clinical validation in collaboration with leading research institutions, with the goal of establishing robust performance metrics for large-scale screening programs. VolitionRX continues to expand its pipeline by exploring new indications and refining assay sensitivity and specificity through ongoing R&D activities.
Headquartered in Belgium, VolitionRX maintains a global presence with subsidiary operations and strategic partnerships across the United States, Europe and Asia. Its management team brings together expertise in molecular diagnostics, regulatory affairs and commercial development, positioning the company to navigate clinical trials, regulatory submissions and market entry. Through alliances with academic centers, contract research organizations and healthcare providers, VolitionRX is working to scale manufacturing, streamline laboratory workflows and accelerate the adoption of its blood-based diagnostic tests worldwide.
